Comparing Black and White Patients in Treatment of Advanced Prostate Cancer and Survival in an Equal Access Health System

被引:0
|
作者
Eaglehouse, Yvonne L. [1 ,2 ]
Darmon, Sarah [1 ,2 ]
Chesnut, Gregory T. [1 ]
Shriver, Craig D. [1 ,3 ]
Zhu, Kangmin [1 ,2 ,4 ]
机构
[1] Uniformed Serv Univ Hlth Sci USUHS, Murtha Canc Ctr Res Program, Dept Surg, 6720A Rockledge Dr,Suite 310, Bethesda, MD 20817 USA
[2] Henry M Jackson Fdn Advancement Mil Med Inc, Bethesda, MD 20817 USA
[3] Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD USA
[4] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA
关键词
Prostate cancer; Cancer treatment; Racial disparities; Prostate cancer survival; Surgical oncology; MEN;
D O I
10.1007/s40615-024-02217-4
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundRacial disparities in prostate cancer treatment and survival in the U.S. have been attributed to differences in access to care and medical insurance. We aimed to compare treatment and survival of advanced prostate cancers between White and Black men in the equal access Military Health System (MHS).MethodsWe accessed the MilCanEpi database to study a cohort of non-Hispanic White and Black men diagnosed with stage III or IV prostate cancer between 1998 and 2014 in the MHS. The racial groups were compared in receiving curative treatment of radical prostatectomy (RP) only, RP with (neo)adjuvant radiation or hormone therapy, radiation only, or combination radiation and hormone therapy; and overall survival using multivariable regression models.ResultsThe study included 1476 White and 531 Black men. Overall, there was no racial difference in receiving any curative treatment (AOR = 0.85, 95% CI = 0.67, 1.08 for Black vs. White). By treatment type, Black men were statistically as likely to receive RP only (AOR = 0.87, 95% CI = 0.67, 1.14), radiation only (AOR = 0.81, 95% CI = 0.49, 1.34), or combination radiation and hormone therapy (AOR = 1.12, 95% CI = 0.71, 1.78) but statistically less likely to receive RP with (neo)adjuvant treatment (AOR = 0.56, 95% CI = 0.37, 0.86) relative to no curative treatment compared to White men. The difference in RP with (neo)adjuvant treatment was also statistically significant among patients with stage III tumors, but not stage IV. Survival was similar overall (AHR = 1.12, 95% CI = 0.88, 1.42 for Black vs. White) and when evaluated by tumor stage.ConclusionsIn the MHS, the overall likelihood to receive any treatment for advanced prostate cancers and survival was similar between races, which might result from universal health care. Racial differences in receipt of RP with (neo)adjuvant treatment, especially for patients with stage III prostate cancer, may be related to factors other than access to care and warrants further research.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer
    Krimphove, Marieke J.
    Cole, Alexander P.
    Fletcher, Sean A.
    Harmouch, Sabrina S.
    Berg, Sebastian
    Lipsitz, Stuart R.
    Sun, Maxine
    Nabi, Junaid
    Nguyen, Paul L.
    Hu, Jim C.
    Kibel, Adam S.
    Choueiri, Toni K.
    Kluth, Luis A.
    Quoc-Dien Trinh
    PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (01) : 125 - 136
  • [22] Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer
    Marieke J. Krimphove
    Alexander P. Cole
    Sean A. Fletcher
    Sabrina S. Harmouch
    Sebastian Berg
    Stuart R. Lipsitz
    Maxine Sun
    Junaid Nabi
    Paul L. Nguyen
    Jim C. Hu
    Adam S. Kibel
    Toni K. Choueiri
    Luis A. Kluth
    Quoc-Dien Trinh
    Prostate Cancer and Prostatic Diseases, 2019, 22 : 125 - 136
  • [23] Comparing prostate specific antigen dynamics between Black patients and White patients
    Johnson, Alexandria
    Brady, Renee
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (12)
  • [24] Comparing prostate specific antigen dynamics between Black patients and White patients
    Johnson, Alexandria
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (01) : 17 - 18
  • [25] STAGE AT PRESENTATION AND SURVIVAL OF WHITE AND BLACK PATIENTS WITH PROSTATE CARCINOMA
    BRAWN, PN
    JOHNSON, EH
    KUHL, DL
    RIGGS, MW
    SPEIGHTS, VO
    JOHNSON, CF
    PANDYA, PP
    LIND, ML
    BELL, NF
    CANCER, 1993, 71 (08) : 2569 - 2573
  • [26] Breast carcinoma survival analysis for African American and white women in an equal-access health care system
    Wojcik, BE
    Spinks, MK
    Optenberg, SA
    CANCER, 1998, 82 (07) : 1310 - 1318
  • [27] Racial Comparisons in Timeliness of Colon Cancer Treatment in an Equal-Access Health System
    Eaglehouse, Yvonne L.
    Georg, Matthew W.
    Shriver, Craig D.
    Zhu, Kangmin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (04): : 410 - 417
  • [28] TREATMENT AND SURVIVAL OF PATIENTS WITH CANCER OF PROSTATE
    不详
    SURGERY GYNECOLOGY AND OBSTETRICS WITH INTERNATIONAL ABSTRACTS OF SURGERY, 1967, 124 (05): : 1011 - &
  • [29] Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system
    Dominitz, JA
    Samsa, GP
    Landsman, P
    Provenzale, D
    CANCER, 1998, 82 (12) : 2312 - 2320
  • [30] RACE, TREATMENT, AND LONG-TERM SURVIVAL FROM PROSTATE-CANCER IN AN EQUAL-ACCESS MEDICAL-CARE DELIVERY SYSTEM
    OPTENBERG, SA
    THOMPSON, IM
    FRIEDRICHS, P
    WOJCIK, B
    STEIN, CR
    KRAMER, B
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (20): : 1599 - 1605